Table 4.
Factors associated with time to a discontinuation of ≥180 days of adalimumab treatment: multivariate Cox proportional hazards regression modela (n = 1335)
| Variable | Hazard Ratio | 95% CI | P‐value |
|---|---|---|---|
| Female sex | 1.14 | 0.98–1.33 | 0.089 |
| Age (per 1 year increment) | 1.01 | 1.00–1.01 | 0.010 |
| SES tertile (1–20 scale) | |||
| Low (1–10) | 1.00 (ref.) | ||
| Intermediate (11–14) | 0.89 | 0.73–1.09 | 0.257 |
| High (15–20) | 0.74 | 0.60–0.91 | 0.002 |
| Unknown | 0.72 | 0.56–0.92 | 0.015 |
| Immigrated after 1988 | 0.84 | 0.68–1.04 | 0.106 |
| Ulcerative colitis vs. other diseases | 1.32 | 1.02–1.71 | 0.034 |
| Concomitant use of prednisone | 1.46 | 1.22–1.75 | <0.001 |
a
Discontinuation was defined as ≥180‐day gap in days of supply. Four patients hospitalized >20% of the follow‐up period were excluded from analysis.